|
Post by peppy on Feb 6, 2018 12:01:32 GMT -5
WESTLAKE VILLAGE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity, effective February 12. Dr. Kendall will report directly to Michael Castagna, Pharm.D., Chief Executive Officer, and will join the company's executive leadership team. He will be based out of MannKind's Westlake Village, California headquarters. "David is a world renowned diabetes expert and represents an important addition to our executive leadership team," said Castagna, Chief Executive Officer of MannKind. "His extensive experience in diabetes research, development, and clinical care in both U.S. and international markets, will be instrumental in helping us achieve the growth potential that we believe Afrezza® clearly possesses." Dr. Kendall's career includes over 30 years of experience in diabetes and metabolism research, clinical management, research, and policy advocacy. Most recently, he served as Research Physician and Vice President of Global Medical Affairs for Lilly Diabetes, and during that time was responsible for all medical affairs activities and guided research and development strategy across multiple geographies. In this role, he worked to re-establish Lilly Diabetes as a world class medical organization — and added to his extensive experience with both injected and mealtime insulins, as well as devices and continuous glucose monitors. Prior to joining Eli Lilly, Dr. Kendall served as Chief Scientific and Medical Officer at the American Diabetes Association, where he was responsible for all medical affairs, medical education, research, outcomes, and medical policy activities. Earlier in his career, Dr. Kendall served as Medical Director at the International Diabetes Center, and the Park Nicollet Clinic, as well as at Amylin Pharmaceuticals. He received his M.D. and completed his Post Graduate Medical Training at the University of Minnesota, and earned a B.A. in Biology from St. Olaf College. "The research and clinical response to Afrezza as a mealtime insulin supports ongoing efforts to establish this product as the standard of care for those living with type 1 or type 2 diabetes," said Dr. Kendall. "Afrezza is the only inhaled fast-acting mealtime insulin on the market, and offers the right patients a flexible, safe, and effective treatment option. I'm thrilled to join MannKind, and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes." The Right Patients: Type One or Type Two Diabetic. 18 or older. Non Smoker. Health Insurance capable of covering Afrezza (insulin human). Continuous Glucose Monitor perferred (3 months to learn how afrezza works.)
|
|
|
Post by nylefty on Feb 6, 2018 12:47:39 GMT -5
Michael Kovacocy Capital Markets Macro and Micro; Capital Sourcing; Media Contributor
MNKD - good news from the company on a key hire. They brought in quality, and quality doesn't join a company which is on the downtrend... Funny how I am crushing the longs on Bitcoin and cryptos and putting in place the clueless naysayers who have been making noise about doom and gloom ever since MNKD was down at $1 just six months ago. $15 near term and $40 in 12-36 months.
|
|
|
Post by mnkdnut on Feb 6, 2018 13:12:03 GMT -5
For me, the "right patients" would be: 1.) patient with a doctor who has the time and depth of knowledge (including important instructions that aren't on the label) to get them through proper titration, 2.) patient who is motivated and engaged enough to put in the work to get through titration, or 3.) patient willing to pay VDEX to coach them through it. I'd rather have 10 patient starts that result in 9 happy, refilling patients than 50 patient starts that result in 10 happy refillers and 40 that are puzzled about why it doesn't seem to work for them.
|
|
|
Post by babaoriley on Feb 6, 2018 13:21:55 GMT -5
I dunno, this guy's education is centered in Minnesota. Perhaps he's wily, though.
|
|
|
Post by nylefty on Feb 6, 2018 13:39:04 GMT -5
Craig Dean@ Michael Kovacocy think any chance this article from a week ago about Lilly having 9 billion from the new tax plan to spend on acquisitions and partnerships And the new hire today from Lilly is associated? Might be nothing but interesting regardless.
Michael Kovacocy
Craig Dean that is some good sleuthing and interesting. I can't comment with certainty on speculation, and if I did know anything specific on this point, I wouldn't be able to comment. So it is clear that I will just have to defer to you and say that it is certainly plausible, why not?
Michael Kovacocy
I would say this. And it isn't rocket science. Mike the CEO continues to deliver what he promised, and is ticking off all the boxes on the company's to do list. This is public info, the list is on loads of presentations, etc. And there are now just a few tick boxes left on the list, and they are biggies. One relating to the subject you have mentioned above. So if I were a betting man, I would expect material news on this point sooner than later. And there is nothing to say that your speculation has any more or less merit than that of others with less optimistic views on the company. I would even be so inclined to say that your thesis makes sense - not so much just for Lilly, but a whole swath of players who might wish to cosy up to MNKD. So the general thrust of your thesis makes sense. Might not be the right company, but makes sense.
|
|
|
Post by joeypotsandpans on Feb 6, 2018 13:45:09 GMT -5
Why would one jump ship from a company the size of Lilly to what SO would term as one that is "speculative" at best? So he is either a fool or a very intelligent individual in the space that sees the future "standard of care". Considering where he is coming from and his background this was a major statement IMO and he must have a lot of confidence in who hired him as well. I like the emphasis on the international experience as well. More importantly is his long standing ties and networking with the insurance side having worked with Lilly's diabetes division. Great work again Mike, stay the course
|
|
|
Post by kc on Feb 6, 2018 14:02:08 GMT -5
IMO they bought his network. Mike is aiming to balance all his elements in the pipeline. He needed an important/expensive role to push Afrezza. There are barriers right now and I assume that he tries to get past them by improving acceptance and awareness. That is more needed than an operational guy running the pipeline in the role of a CMO. WINNER WINNER CHICKEN DINNER...........
VERY CREDIBLE HIRE WHO CAN PRESENT THE STAT STUDY AT ADA. WELL KNOWN ADA PRESENTER.
|
|
|
Post by kc on Feb 6, 2018 14:04:14 GMT -5
So maybe Lilly will acquire mnkd? They need a great Meal time insulin product. Then yes he knows the right people at Lilly to advance the case for a partnership.
|
|
|
Post by gamblerjag on Feb 6, 2018 14:12:13 GMT -5
Michael Kovacocy Capital Markets Macro and Micro; Capital Sourcing; Media Contributor
MNKD - good news from the company on a key hire. They brought in quality, and quality doesn't join a company which is on the downtrend... Funny how I am crushing the longs on Bitcoin and cryptos and putting in place the clueless naysayers who have been making noise about doom and gloom ever since MNKD was down at $1 just six months ago. $15 near term and $40 in 12-36 months.
boy I would love mike k to start decreasing his timeline to $40 in 9 to 33 months. Yes sports I know I'm literal :-)
|
|
|
Post by kc on Feb 6, 2018 14:25:02 GMT -5
Editorial contributor to the www.endocrine.org/ ENDO 2018 March 17-20, 2018 McCormick Place West Chicago, Illinois
Join us at ENDO 2018, the most well attended and valued translational endocrinology meeting in the world. Bringing together leading experts, researchers, and the most respected clinicians in the field, ENDO represents a convergence of science and practice that highlights and facilitates breakthrough discoveries in the field of endocrinology. Spend time connecting with peers and colleagues, exchanging ideas and information, and getting out in front of the latest trends and advancements in hormone health.
Key Dates: Late-Breaking Abstract Submission: January 11 – February 5, 2018
Maybe they STAT study will be released at ENDO 2018.
Probably too late to get a Booth at the event.
As an exhibitor at ENDO you will reach your prospects and gain recognition for your company’s products and services among 7,500+ endocrinologists. Here are some of the ways we build traffic and help companies exceed their exhibit expectations. The schedule contains 1 hour of completely unopposed time on all three days when the Expo is open
ENDO 2017 attendance totaled more than 7,500, including 5,900+ clinical endocrinologists, and 2,350 abstracts were presented Expo Theater Sessions were sold out, and averaged 150 attendees each – maximum capacity
Poster sessions are interspersed throughout the Expo Necessities like food stations, complimentary coffee, recharging stations, and more are all available in the Expo Science Hubs – Two locations will be located in the Expo Hall to host a wide variety of programs including the top scoring posters
Late-Breaking Submission Deadline: Monday, February 5, 2018, 1:00 PM EST
At ENDO 2018, you can expect leaders in endocrine practice and hormone research to share their latest breakthroughs that advance science and shape the future of patient care. By submitting your research for presentation at ENDO, you are not only helping to facilitate that exchange of information, you also gain valuable feedback from peers while fostering relationships for potential new partners.
By submitting your research for presentation at ENDO, you will not only have the chance to get your research in front of an engaged audience, but all accepted abstracts will also be published in Endocrine Reviews. Endocrine Reviews is ranked 4th of 138 journals in the category of Endocrinology & Metabolism with an impact factor of 15.745.
The media look to ENDO to discover the latest groundbreaking research and treatments. News articles highlighting ENDO 2017 reached nearly 2 billion unique visitors on online news sites and nearly 447,000 print readers. Stories about the meeting appeared in top-tier outlets, including The Wall Street Journal, Yahoo! Beauty, Reuters news wire service, Men’s Health magazine, International Business Times, Health magazine, London newspaper The Daily Telegraph, and STAT News, a health news site run by the owners of The Boston Globe
www.betacellsindiabetes.org/about/author?page=1 A resource for healthcare providers established by The Endocrine Society.
Our mission:
Engage primary care physicians in pathophysiology-based clinical decision making through an interactive educational format that stimulates debate and encourages physicians to incorporate the new science into their treatment regimens for patients with type 2 diabetes.
Background
In September, 2010, The Endocrine Society launched BetacellsinDiabetes.org based on recommendations from a meeting which brought together basic researchers, clinical endocrinologists, and primary care physicians (PCPs) to discuss the need to improve understanding of the role of beta cells as key drivers in the natural history of T2DM. The hope is that this effort will aid primary care physicians in the interpretation of concepts of disease pathogenesis, such as beta cell dysfunction, and improve medical decision-making in T2DM.
Funders
BetacellsinDiabetes.org is supported by an educational grant from Novo Nordisk, Inc and contributions from Lilly USA, LLC (for further information concerning Lilly grant funding (visit http://www.lillygrantoffice.com) and Merck & Co., Inc.
|
|
|
Post by dreamboatcruise on Feb 6, 2018 14:30:57 GMT -5
C raig Dean@ Michael Kovacocy think any chance this article from a week ago about Lilly having 9 billion from the new tax plan to spend on acquisitions and partnerships And the new hire today from Lilly is associated? Might be nothing but interesting regardless. Michael Kovacocy
Craig Dean that is some good sleuthing and interesting. I can't comment with certainty on speculation, and if I did know anything specific on this point, I wouldn't be able to comment. So it is clear that I will just have to defer to you and say that it is certainly plausible, why not? Michael Kovacocy
I would say this. And it isn't rocket science. Mike the CEO continues to deliver what he promised, and is ticking off all the boxes on the company's to do list. This is public info, the list is on loads of presentations, etc. And there are now just a few tick boxes left on the list, and they are biggies. One relating to the subject you have mentioned above. So if I were a betting man, I would expect material news on this point sooner than later. And there is nothing to say that your speculation has any more or less merit than that of others with less optimistic views on the company. I would even be so inclined to say that your thesis makes sense - not so much just for Lilly, but a whole swath of players who might wish to cosy up to MNKD. So the general thrust of your thesis makes sense. Might not be the right company, but makes sense. One doesn't have more merit than the other, yet he's inclined to agree with one over the other. Does this guy read what he writes, or does he not realize that doesn't make logical sense.
|
|
|
Post by porkini on Feb 6, 2018 14:59:50 GMT -5
Editorial contributor to the www.endocrine.org/ ENDO 2018 March 17-20, 2018 McCormick Place West Chicago, Illinois
Join us at ENDO 2018, the most well attended and valued translational endocrinology meeting in the world. Bringing together leading experts, researchers, and the most respected clinicians in the field, ENDO represents a convergence of science and practice that highlights and facilitates breakthrough discoveries in the field of endocrinology. Spend time connecting with peers and colleagues, exchanging ideas and information, and getting out in front of the latest trends and advancements in hormone health.
Presentation: SUN-087 / SUN-087 - Subcutaneous Insulin Resistance Syndrome (SIRS) and Use of Inhaled Insulin
|
|
|
Post by kc on Feb 6, 2018 15:18:10 GMT -5
LinkedIn profile has not been updated. but interesting has he must have just left Lilly
David Kendall •
Vice President - Medical Affairs - Lilly Diabetes Eli Lilly and Company • University of Minnesota Medical School
Experience Eli Lilly and Company
Vice President - Global Medical Affairs - Lilly Diabetes
Company Name Eli Lilly and Company
Dates Employed Jun 2014 – Present
Employment Duration •3 yrs 9 mos
Location Indianapolis, Indiana Eli Lilly and Company
Distinguished Medical Fellow - Global Medical Affairs - Lilly Diabetes
Company Name Eli Lilly and Company
Dates Employed Jul 2011 – Jun 2014
Employment Duration •3 yrs
Location indianapolis, indiana area
|
|
|
Post by peppy on Feb 6, 2018 15:26:40 GMT -5
alrighty then, being that MNKD's new chief Medical Officer is connected at some level with the University of Minnesota, I say he calls the physician endo groups at the University of Minnesota and they talk.
Eli Lilly and Company • University of Minnesota Medical School
United Health headquartered in Minnesota, hmmmm
|
|
|
Post by mnholdem on Feb 6, 2018 15:43:02 GMT -5
I dunno, this guy's education is centered in Minnesota. Perhaps he's wily, though. ...and I suppose that you also think that Minnesota's Mayo Clinic is just an urgent care center?
|
|